→
Resmed Inc (RMD) is currently trading at $201.88, reflecting a market cap of $29.28B, with a notable year-over-year EPS growth of 16.47% and revenue growth of 10.28%. The company's strong fundamentals are supported by a robust ROE of 24.41% and a healthy current ratio of 3.01, suggesting significant liquidity. Given these metrics and the consensus rating of 4 Strong Buy and 12 Buy from analysts, RMD is well-positioned for future growth.
Investors should consider accumulating RMD shares, given its strong growth metrics and positive analyst sentiment.
Resmed Inc is expected to continue its upward trajectory, as evidenced by its consistent earnings beats, including $2.86 in Q3 2026 against an estimate of $2.82. Additionally, the stock's 52-week high of $293.81 presents significant upside potential from its current price.
While Resmed has shown impressive growth, the P/E ratio of 19.27 indicates that the stock may be overvalued compared to historical averages, especially if growth slows. Furthermore, the bearish sentiment in the broader market could pose risks to the stock's performance.
Want AI analysis of your entire portfolio?
Helm Terminal connects to your brokerage, analyzes every holding, and delivers actionable intelligence weekly.
Get started freeHelm provides financial data for informational purposes only. This is not financial, investment, or tax advice. Consult a qualified professional before making financial decisions.
Helm's AI rates RMD as Bullish. Investors should consider accumulating RMD shares, given its strong growth metrics and positive analyst sentiment.
While Resmed has shown impressive growth, the P/E ratio of 19.27 indicates that the stock may be overvalued compared to historical averages, especially if growth slows. Furthermore, the bearish sentiment in the broader market could pose risks to the stock's performance.
Resmed Inc is expected to continue its upward trajectory, as evidenced by its consistent earnings beats, including $2.86 in Q3 2026 against an estimate of $2.82. Additionally, the stock's 52-week high of $293.81 presents significant upside potential from its current price.
Resmed Inc (RMD) is currently trading at $201.88, reflecting a market cap of $29.28B, with a notable year-over-year EPS growth of 16.47% and revenue growth of 10.28%. The company's strong fundamentals are supported by a robust ROE of 24.41% and a healthy current ratio of 3.01, suggesting significant liquidity. Given these metrics and the consensus rating of 4 Strong Buy and 12 Buy from analysts, RMD is well-positioned for future growth.
Resmed Inc (RMD) is currently trading at $201.88, reflecting a market cap of $29.28B, with a notable year-over-year EPS growth of 16.47% and revenue growth of 10.28%. The company's strong fundamentals are supported by a robust ROE of 24.41% and a healthy current ratio of 3.01, suggesting significant liquidity. Given these metrics and the consensus rating of 4 Strong Buy and 12 Buy from analysts, RMD is well-positioned for future growth. Our overall verdict is Bullish.
Helm Terminal offers free AI-powered stock analysis for RMD at helmterminal.dev/analyze/RMD, updated continuously during US market hours. No signup required.
Helm's analysis is generated by an AI model from live market data. It identifies risk signals, opportunities, and key metrics based on current fundamentals, recent price action, and analyst consensus. It does not execute trades, issue certified investment advice, or predict future prices.
Not financial advice. Informational use only. AI-generated content may contain errors. Consult a licensed financial advisor before making investment decisions. Helm Terminal is not registered as an investment advisor.